Skip to main content

Global Digital Pathology Market Size Report 2021-2028 | Share, Growth Factors, Trends, Restraining Factors, Competitive Landscape, Revenue, Forecast Analysis

Written by Customer Service on . Posted in Mergers And Acquisitions.

Key Players Covered in the Digital Pathology Market Research Report are 3DHISTECH – The Digital Pathology Company, Mikroscan Technologies, Inc., Objective Pathology Services, Hamamatsu Photonics, Roche Diagnostics Danmark, Primera Technology, Biogenuix Medsystems Pvt Ltd and other key market players

Pune, India, Oct. 14, 2021 (GLOBE NEWSWIRE) — The Global Digital Pathology Market is likely to expand due to the rising use of advanced diagnostic tools for prompt diagnosis of chronic diseases. According to a report, titled “Digital Pathology: Global Market Analysis, Insights and Forecast, 2018-2025,” the market is likely to grow due to the increasing number of people diagnosed with related diseases.

The Market is likely to grow in the forthcoming years due to recent technological advancements in pathology devices. Recent advancements have induced increasing operational efficacy, which is a major factor propelling growth in the global digital pathology market


Sample PDF Brochure of Digital Pathology Market: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/digital-pathology-market-100229

A hospital, research laboratory and any related center can transfer the image anywhere in the world within no time. This significantly reduces the time to treat and diagnose and eliminates the need to call upon a specialist for a consultation. The aforementioned factors have created an increasing adoption of digital pathology over other methods.

FDA Clearance for Philips’ Intellisite Pathology to Bode Well for Digital Pathology Market

In April 2017, the FDA gave its approval to Philips’ Intellisite Pathology (PIPS) for manufacturing and sale in the U.S. This was the first ever digital pathology system in the market with FDA clearance. According to Fortune Business Insights, approval to Philips’ Intellisite will encourage other pathology device manufacturers to come up with their own patents and use PIPS as a reference.

Secondly, pathologists and related clinical centers that had held off buying any type of pathology systems, until they would receive clearance from a regulatory authority, would now willingly invest and buy Philips’ Intellisite due to the FDA approval. Such factors will lead to the entry of newer market players and also encourage existing companies to improvise as well as improve their product to shake off competition from Philips.


For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/digital-pathology-market-100229


Key Segmentation of Digital Pathology Market:

by Technology

  • Whole Slide Imaging
  • Image Analytics Information
  • Digital Cytopathology
  • Digital Holography
  • Microscopy

by Application

  • Hematology Analysis
  • Blood Cell Counting
  • Urine Sediment Analysis
  • Disease Diagnosis

by End User

  • Pathology Laboratories
  • Hospitals
  • Pharmaceutical and Biotechnology Companies
  • Diagnostic Centers

by Geography

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa


Quick Buy Digital Pathology Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/100229


Use of Digital Pathology in Surgical Procedures Has Proven Hugely Beneficial

In surgical pathology, the diagnosed tissue can be detected, diagnosed, treated, and then incised into paper thin slices. These slices are then mounted upon glass slides, which are then examined by pathologists under microscopic conditions. This method was a first of its kind and possesses very high efficiency, besides offering clear and sharp images.

Furthermore, digital slides can be reproduced as many times as needed. Therefore, the use of pathology in surgical procedures ensures higher surgical efficiency and reduces the time required for diagnosis and operation. This has led to rapid adoption of digital pathology around the world.


Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/digital-pathology-market-100229


Some of the Main Key Players Covered in the Digital Pathology Market Report

  • 3DHISTECH – The Digital Pathology Company
  • Mikroscan Technologies, Inc.
  • Objective Pathology Services
  • Hamamatsu Photonics
  • Roche Diagnostics Danmark
  • Primera Technology
  • Biogenuix Medsystems Pvt Ltd
  • Indica Labs
  • Philips Benelux
  • Inspirata
  • LigoLab LLC
  • Leica Biosystem
  • Olympus Corporation of the Americas
  • Nikon Optical Canada Inc.


Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/queries/digital-pathology-market-100229


About Us:

Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them to address various challenges distinct to their businesses. Our aim is to empower them with holistic market intelligence, providing a granular overview of the market they are operating in.


Contact Us:

Fortune Business Insights™ Pvt. Ltd.

308, Supreme Headquarters,

Survey No. 36, Baner,

Pune-Bangalore Highway,

Pune – 411045, Maharashtra, India.


Phone:

US :+1 424 253 0390

UK : +44 2071 939123

APAC : +91 744 740 1245

Email: sales@fortunebusinessinsights.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.